Powered by

DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

Nov 20, 2018 - PR Newswire

PR Newswire

DelMar Pharmaceuticals, Inc.(NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, presented scientific updates, including data from two ongoing clinical trials, at the 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) held on November 15-18, 2018 in New Orleans, LA.

"In our much-awaited Phase 2 study of VAL-083 in patients with MGMT-unmethylated, Bevaciz...